Resistance to Herceptin (trastuzumab) in HER2 positive breast cancers: the role of calcium signalling. [ 2015 - 2018 ]

Research Grant

Researchers: Prof Gregory Monteith (Principal investigator) ,  Prof Sarah Roberts-Thomson

Brief description The monoclonal antibody therapy trastuzumab has revolutionized the treatment of women with Her2 positive breast cancer. Unfortunately some Her2 positive breast cancers do not respond to this therapy or gradually develop resistance. This project will define how an important cellular signal is remodeled in breast cancers resistant to trastuzumab. The ability of modulators of this signaling pathway to alter the sensitivity of breast cancers to trastuzumab will also be determined.

Funding Amount $AUD 620,292.28

Funding Scheme Project Grants

Notes Standard Project Grant